Global Postpartum Hemorrhage Treatment Devices Market to reach USD 926.1 million in 2023

The Global postpartum hemorrhage treatment devices market was valued at USD 604.4 million in 2014 and is estimated to reach USD 926.1 million in 2023, expanding at a CAGR of 4.9% from 2015 to 2023.According to the World Health Organization (WHO), postpartum hemorrhage (PPH) is the principal cause of maternal mortality, accounting for more than 30% of all maternal deaths in developed as well as developing countries. This condition can be defined as blood loss in excess of 500 mL after vaginal delivery or more than 1,000 mL after cesarean delivery. Moreover, if such blood loss occurs within 24 hours of delivery, it is categorized as early or primary PPH. If such blood loss occurs after 24 hours of delivery, it is termed as late or secondary PPH. The organization also stated that more than 14 million women suffer from PPH globally each year, of these 150,000 women die annually.

 

Major factors likely to boost the growth of the market are high prevalence of PPH in various countries, growing number of educational and training initiatives by governments, and escalating risk factors related to PPH. However, lack of product awareness in the emerging economies and low acceptance of unconventional preventive devices would hamper the growth of the postpartum hemorrhage treatment devices market during the forecast period.

 

Get Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=6164

 

Non-pneumatic anti-shock garment (NASG), Uniject prefilled injection system, and uterine balloon tamponade collectively form the postpartum hemorrhage treatment devices market. The uterine balloon tamponade segment has been sub-segmented into Foley catheters, condom catheters, and others. Uterine balloon tamponade was the largest segment of the PPH treatment devices market, accounting for approximately 46.3% share in 2014. The segment is expected to maintain its leadership position during the forecast period. Factors such as ultra-low cost, easy availability, and high effectiveness have been attributed to the largest share of the uterine balloon tamponade segment. In addition, several public health organizations such as the International Confederation of Midwives (ICM), the American College of Obstetricians and Gynecologists, and the World Health Organization (WHO) recognize UBT devices as an ultra-affordable medical alternative that could significantly help in the management of PPH in resource-poor health care settings where pharmaceutical and surgical interventions are not readily available.